<- Go home

Added to YB: 2024-02-22

Pitch date: 2024-02-16

CPH.TO [bullish]

Cipher Pharmaceuticals Inc.

+147.16%

current return

Author Info

No bio for this author

Company Info

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

Market Cap

CAD 330.8M

Pitch Price

CAD 7.74

Price Target

N/A

Dividend

N/A

EV/EBITDA

13.65

P/E

12.45

EV/Sales

6.52

Sector

Pharmaceuticals

Category

value

Show full summary:
$CPH.TO: Robust Financials, Downside Protection, and Growth Potential

$CPH.TO: $42M cash, Epuris $11M rev,$10M profit,$20M NOLs=$91M NPV 15% disc rate=$4.76/sh CAD. Licensing adds $10M NPV=$0.37/sh. Bearish valuation=$5.14/sh (30% downside). Mgmt focused on buybacks, diversified biz limits risk. Compelling opportunity given upside in Epuris & Absorica.

Read full article (1 min)